Home | Novugen

A Decade of

Accelerating Affordable Medicine

Our commitment to breaking healthcare barriers drives every milestone we have accomplished over the past decade.

Journey with us to discover how ten years of pharmaceutical excellence have translated into better health outcomes for patients worldwide.

2016

Commenced the first high-containment API R&D Centre in ASEAN
Commenced the first Finished Product R&D Centre in ASEAN to develop complex products meeting USFDA standards

2017

Commenced the first high-containment oncology finished product R&D Centre in ASEAN to develop OEB5 products meeting USFDA standards
Pioneered Southeast Asia industry benchmarks by delivering first-to-market medicines through non-infringing formulations

2020

Commissioned Novugen Pharma's state-of-the-art Oral Solid Dosage manufacturing facility with NPRA approval

2021

Commissioned Novugen Oncology's state-of-the-art Oral Solid Dosage manufacturing facility with NPRA approval

2022

Attained USFDA approval for Novugen Pharma’s manufacturing facility – First in Malaysia and only one in Southeast Asia
Novugen Oncology’s flagship product – Abiraterone Acetate, received ANDA approval for the US market
Launched Novugen Pharma’s first products, Novugab (Pregabalin) and Tadigra (Tadalafil) to all healthcare sectors in Malaysia

2023

Received USFDA approval for Novugen Oncology’s manufacturing facility – First in Malaysia and only one in Southeast Asia
Novugen Oncology became the first USFDA approved, high containment (OEB5) Finished Product manufacturing facility in Southeast Asia

2024

Novugen became the 1st pharmaceutical company in Southeast Asia to export oncology generics to the USA
Novugen secured its first exclusive first-to-file status for Trametinib for the US market
Novugen Pharma achieved ZERO Form 483 Citations in USFDA Surveillance Inspection Audit – a reflection of Novugen’s global quality standards

2025

Novugen became Malaysia’s fastest growing pharmaceutical company, rising to Top 14 National Ranking by revenue within 3 years of commercialization

2026

Novugen launched Sacubitril Valsartan, a blockbuster cardiovascular drug, being among the first wave of generics globally.
Novugen celebrates 10 years of pharmaceutical innovation and excellence

Over 70 Complex
Finished Products

More than 40 Product Launches (Malaysia)

10 ANDA Approvals (USA)

280

280 Products in 13 Countries (ASEAN, MENA, LATAM)

Top 14 Pharmaceutical
Company in Malaysia
by revenue

5260

Our products span across 5,260 hospitals, clinics, and pharmacies nationwide

A Decade of Impact

Guided by scientific innovation, R&D excellence, and a commitment to challenging the status quo, we continue to push the boundaries of accessible healthcare solutions.

Since 2016, Novugen has grown into a leading pharmaceutical company specializing in niche and difficult-to-formulate generics across multiple therapeutic areas, bringing affordable, life-changing medicines to patients and communities worldwide.

Latest News

28 April 2026

Year In Review 2025 Highlights

25 Sep 2025

Novugen Launched Sacubitril and Valsartan Tablets in the U.S. Following Recent ANDA Approval

14 Aug 2025

Novugen Secured Patent Grant for Amlodipine and Valsartan Process Innovation

30 June 2025

Malaysia at the Forefront of Driving ASEAN's Pharmaceutical Self-Reliance

16 May 2025

Novugen Oncology Receives Approval from UAE MoHAP

17 April 2025

Novugen and Hikma Pharmaceuticals Announce Strategic Partnership

14 Feb 2025

Novugen Strengthens Ties with Uzbekistan's Ministry of Health

31 Dec 2024

Year in Review: Novugen 2024 Highlights

Growing with Novugen

At Novugen, growth is built together. Powered by over 800 Novugenians driving impact around the globe, our people are the driving force behind everything we do. Discover how Novugenians are growing, impacting lives, and shaping the future with Novugen.

Digital biological twins and organoids might sound like sci-fi, but they're real â€“ and we're using them to fight cancer